These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36645960)

  • 1. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
    Zhang H; Yang Y; Li X; Yuan X; Chu Q
    Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
    Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
    J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
    Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
    Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
    J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
    Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
    Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DLL3: an emerging target in small cell lung cancer.
    Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
    J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
    Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
    Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
    Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
    Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
    Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.
    Lin S; Zhang Y; Yao J; Yang J; Qiu Y; Zhu Z; Hua H
    J Transl Med; 2024 Aug; 22(1):766. PubMed ID: 39143619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
    Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
    Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
    Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.